miR-142-5p regulates the progression of diabetic retinopathy by targeting IGF1

Int J Immunopathol Pharmacol. 2020 Jan-Dec:34:2058738420909041. doi: 10.1177/2058738420909041.

Abstract

As one of leading causes of blindness, diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus (DM). Despite significant efforts have been devoted to investigate DR over the years, the molecular mechanisms still remained unclear. Emerging evidences demonstrated that microRNAs (miRNAs) were tightly associated with pathophysiological development of DR. Hence, this study was aimed to illustrate the role and molecular mechanisms of miR-412-5p in progression of DR. Streptozotocin (STZ) treatment in rats and human retinal endothelial cell (HREC) models were used to simulate DR conditions in vivo and in vitro. Hematoxylin-eosin (HE) staining was used to demonstrate the morphology of retinal tissues of rats. Qualitative real-time polymerase chain reaction (qRT-PCR) detected miR-142-5p and vascular endothelial growth factor (VEGF) expression levels. Cell counting kit-8 (CCK8) assay and immunofluorescence (IF) measured the cell proliferation rates. Western blot tested the expression status of IGF1/IGF1R-mediated signaling pathway. Dual-luciferase reporter assays demonstrated the molecular mechanism of miR-142-5p. miR-142-5p level was down-regulated in retinal tissues of DR rats and high glucose (HG)-treated HRECs. Insulin-like growth factor 1 (IGF1) was identified as a direct target of miR-142-5p. The reduced miR-142-5p level enhanced HRECs proliferation via activating IGF/IGF1R-mediated signaling pathway including p-PI3K, p-ERK, p-AKT, and VEGF activation, ultimately giving rise to cell proliferation. Either miR-142-5p overexpression or IGF1 knockdown alleviated the pathological effects on retinal tissues in DR rats. Collectively, miR-142-5p participated in DR development by targeting IGF1/p-IGF1R signaling pathway and VEGF generation. This miR-142-5p/IGF1/VEGF axis provided a novel therapeutic target for DR clinical treatment.

Keywords: IGF1; VEGF; diabetic retinopathy; miR-142-5p.

MeSH terms

  • Animals
  • Cell Line
  • Diabetes Mellitus, Experimental / pathology
  • Diabetic Retinopathy / genetics*
  • Diabetic Retinopathy / pathology
  • Endothelial Cells / drug effects
  • Glucose / pharmacology
  • Humans
  • Insulin-Like Growth Factor I / genetics*
  • MAP Kinase Signaling System / genetics
  • Male
  • MicroRNAs / genetics*
  • Oncogene Protein v-akt / genetics
  • Phosphatidylinositol 3-Kinases / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, IGF Type 1 / genetics
  • Retina / pathology
  • Signal Transduction
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • MIRN142 microRNA, rat
  • MicroRNAs
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1
  • Oncogene Protein v-akt
  • Glucose